Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Dr. Andrea Adams-Miller, Founder of The RED Carpet Connection, LLC and The SubConscious Connection, LLC, has released a ...

Under a new indefinite delivery, indefinite quantity contract structure, Veterans Affairs said it can procure the data and ...

AI Impact highlights Rivian’s autonomy strategy, hybrid AI gains in healthcare, AGI skepticism, exec moves and AI Impact ...

The sponsored level I ADR listing strengthens U.S. investor access, settlement quality and market credibility, the company ...

Structure Therapeutics (GPCR) announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living ...

Coinlocally has formally announced the expansion of its trading platform to include two structured offerings aimed at supporting the retail trading community: a Forex trading service and a proprietary ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

For the millions of Americans touched by Alzheimer’s disease, 2025 brought major advances in understanding of brain health ...

Structure Therapeutics stock soars 103% as its oral obesity drug aleniglipron shows strong Phase 2b weight-loss results.